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To examine concurrent validity and discrimination of modified minimal disease activity 
(mMDA) criteria in peripheral spondyloarthritis (pSpA) following OMERACT filter principles 
and determine predictors of mMDA response. 
Methods 
Four mMDA versions were derived in the ABILITY-2 study using the SPondyloArthritis 
Research Consortium of Canada (SPARCC) or Leeds Enthesitis Index (LEI) but excluding 
psoriasis. To assess concurrent validity, mMDA versions were correlated with Peripheral 
SpondyloArthritis Response Criteria (PSpARC) remission, Ankylosing Spondylitis Disease 
Activity Score for inactive disease (ASDAS ID), and physician global. Treatment discrimination 
was assessed between adalimumab and placebo at week 12. 
Multiple logistic regression was used to determine baseline predictors of long-term mMDA 
responses and sustained mMDA. 
Results 
The four mMDA versions showed a stronger positive correlation with PSpARC remission 
(rtet>0.95) versus ASDAS ID (rtet>0.75) at week 12 and years 1-3 and were able to show 
discrimination (p<0.001).  
Responsiveness was shown at week 12; significantly more patients receiving adalimumab versus 
placebo achieved all four versions of mMDA. Approximately 40-60% of adalimumab-treated 
patients achieved mMDA-LEI or SPARCC at years 1-3. 
Achieving mMDA response after 12 weeks of adalimumab treatment was a robust positive 
predictor of attaining long-term mMDA through 3 years (odds ratios: 11.38-27.13 for mMDA-
LEI; 17.98-37.85 for mMDA-SPARCC). 
Conclusions 
All four versions of mMDA showed concurrent validity and discriminated well between 
adalimumab and placebo treatment groups. Early mMDA response is a more consistent predictor 
of long-term mMDA achievement than baseline characteristics. The 5 of 6 versions of mMDA 
could be an appropriate treatment target in pSpA patients. 
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SIGNIFICANCE AND INNOVATIONS 
• In patients with peripheral spondyloarthritis (pSpA), using 4 modified minimal disease 
activity (mMDA; excluding psoriasis) versions following aspects of the OMERACT filter 
criteria, the mMDA version that used either of the PsA validated entheseal indices (Leeds 
Enthesitis Index and SPondyloArthritis Research Consortium of Canada) discriminated 
well between adalimumab and placebo treatment groups.  
• Similar to MDA definitions used in PsA, the data presented here support the concurrent 
validity and discrimination of mMDA using either entheseal index depending on 
physician’s preference 
• Early mMDA response is a more consistent predictor of long-term mMDA achievement 
than baseline characteristics, and identification of factors that predict long-term mMDA 
response in pSpA patients would help to facilitate treatment decisions 
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Peripheral spondyloarthritis (pSpA) encompasses patients with predominantly peripheral 
symptoms such as peripheral arthritis, dactylitis, and/or enthesitis.(1, 2) To date, most studies in 
the field of pSpA have focused on psoriatic arthritis (PsA). Relatively few outcome measures 
have been developed specifically for non-psoriatic pSpA. Due to a lack of validated outcome 
measures in non-psoriatic pSpA, recent studies have used varying outcome measures such as 
improvement in patient’s global assessment of disease (PtGA) used in the TIPES trial,(3) ≥40% 
improvement in Peripheral SpondyloArthritis Response Criteria (PSpARC40) developed as a 
novel primary endpoint in the ABILITY 2 trial,(4) or clinical remission, defined as absence of 
peripheral arthritis, enthesitis, and dactylitis used in golimumab CRESPA trial.(5)  
The discriminatory capacity of different outcome measures was evaluated in patients with 
pSpA from the TIPES and ABILITY-2 studies.(6) Although most of the outcome measures used 
in pSpA studies distinguished between active treatment and placebo, not all of the relevant pSpA 
disease manifestations were fully captured. Therefore, it may be worthwhile to develop and 
validate alternative pSpA-specific composite indices that better capture relevant disease aspects 
of pSpA.  
The minimal disease activity (MDA) was developed and validated in patients with PsA to 
define a specific disease activity state and have been validated in interventional clinical trials and 
observational studies and recommended as a treatment target in patients with PsA.(7-12) 
However, the potential applicability of MDA to other forms of pSpA has not yet been 
established. If the measure shows validity in defining a disease state in pSpA, identification of 
factors that predict long-term modification of the MDA (mMDA) response in pSpA patients 
would help to facilitate decisions regarding treatment initiation and maintenance. 
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The purpose of this analysis was to examine the concurrent validity and discrimination of 
a mMDA criteria (excluding psoriasis) following aspects of the OMERACT filter (including 
truth and discrimination), and to identify predictors of long-term mMDA response following 
adalimumab treatment in patients with pSpA included in the ABILITY-2 study.(13) 
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PATIENTS AND METHODS 
Patient population 
Results from ABILITY-2 (NCT01064856), a phase 3 randomized, double-blind, placebo-
controlled study were reported previously.(4, 14) Briefly, ABILITY-2 included adult patients 
(≥18 years) with pSpA who fulfilled the Assessment of SpondyloArthritis international Society 
(ASAS) criteria for pSpA, with symptom onset at least 3 months prior to study entry.(1) To 
avoid overlap in patient populations, patients with a history of psoriasis or PsA or ankylosing 
spondylitis (AS) were excluded from the study. Patients were randomized 1:1 to receive 
adalimumab 40 mg or placebo every other week during the 12-week placebo-controlled period, 
followed by open-label extension during which they received open-label adalimumab for up to 
144 weeks. Patients underwent a total of 16 visits during the open-label period of the study.(14) 
In this analysis, data from the ABILITY-2 study was used to examine the concurrent validity and 
discrimination of modified (m) versions of MDA and identify predictors of long-term mMDA 
following adalimumab treatment. 
Outcome measures 
The original MDA for PsA is defined as achieving ≥5 of the following 7 criteria: tender 
joint count of 78 joints (TJC78) ≤1, swollen joint count of 76 joints (SJC76) ≤1, Psoriasis Area 
and Severity Index (PASI) ≤1, patient assessment of pain (patient pain) ≤15 on a 0–100 mm 
visual analog scale (VAS), PtGA ≤20 on a 0–100 mm VAS, Health Assessment Questionnaire-
Disability Index (HAQ-DI) ≤0.5, and tender entheseal points (assessed bilaterally at 2 sites) 
≤1.(7)  
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However, skin outcome measures (Psoriasis Area Severity Index [PASI] or Body Surface 
Area [BSA]) were not included in ABILITY-2, as patients with psoriasis or PsA were excluded. 
Hence, the MDA criteria were modified for the non-psoriatic pSpA population by removing the 
psoriasis skin component (PASI) and two modifications were tested defined as achieving at least 
4 or 5 out of the 6 mMDA components mentioned above but excluding the PASI. A previous 
study showed that the Leeds Enthesitis Index (LEI) and the SPondyloArthritis Research 
Consortium of Canada (SPARCC) enthesitis index were able to better discriminate between 
adalimumab and placebo treatment responses compared with the Maastricht Ankylosing 
Spondylitis Enthesitis Score (MASES) in patients with pSpA,(15) but it has not been 
investigated whether the SPARCC or LEI instrument is better in pSpA. Thus, enthesitis was 
assessed by either LEI or SPARCC enthesitis index in this analysis. The different enthesitis 
measures are described in online supplementary Table S1.To summarize, at each time point, the 
following 4 versions of mMDA were evaluated: mMDA 4/6 (LEI) (achieving 4 out of 6 mMDA 
components and use of LEI); mMDA 5/6 (LEI) (achieving 5 out of 6 mMDA components); 
mMDA 4/6 (SPARCC) (use of SPARCC enthesitis index); and mMDA 5/6 (SPARCC). 
Peripheral SpA Response Criteria (PSpARC) remission and Ankylosing Spondylitis 
Disease Activity Score for Inactive Disease (ASDAS ID, ASDAS <1.3) were used as outcome 
measures.(4, 16) Disease remission based on PSpARC was defined as achieving SJC ≤1 and ≥4 
out of following 5 criteria: PtGA ≤20, Patient pain ≤20, TJC78 ≤1, enthesitis count (based on 29 
enthesitis sites) ≤1, and dactylitis count ≤1.(4)  
Statistical methods 
Given that there is no true gold standard for disease control in pSpA, criterion validity 
could not be assessed. Instead, concurrent validity was assessed by correlation of the 4 versions 
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of the mMDA with related disease outcome measures. Correlation analyses were therefore 
performed with PSpARC remission and ASDAS ID by tetrachoric correlation (rtet) applicable for 
binary outcomes;(17) in addition, the correlation between the 4 versions of mMDA and 
Physician’s Global Assessment of disease activity (PhGA) was evaluated by point-biserial 
correlation (rpb) applicable for one continuous and one binary outcome.(18)  
The discriminatory ability of all 4 versions of mMDA, PSpARC remission, and ASDAS 
ID comparing adalimumab treatment versus placebo at week 12 was assessed using Pearson’s χ2 
test (higher score meaning better discrimination). To differentiate between the 4 candidate 
mMDA and examine their threshold of meaning, residual disease in different domains despite 
achieving these candidate targets was analysed. 
Patients who received at least 12 weeks of adalimumab treatment during the placebo-
controlled period or open-label extension with data available after 12 weeks of adalimumab 
exposure and at years 1, 2, and 3 were included in this analysis (as observed data are presented). 
The number and proportion of patients achieving an mMDA response over time was calculated.  
Multiple logistic regression with stepwise variable selection was used to determine 
predictors of long-term 5/6 mMDA responses at years 1, year 2, and year 3, respectively, and 
sustained mMDA response at any time point (defined as achieving mMDA for at least 24 
consecutive weeks.(14) Two sets of candidates predicting variables were considered in the model 
selection: baseline patient demographics and disease characteristics alone and also the same 
potential predictors along with mMDA response after 12 weeks of adalimumab exposure 
(mMDA12). Candidate baseline variables included in the analysis were age, sex, pSpA duration 
(in years), Human Leucocyte antigen B27 (HLA-B27) status (positive versus negative), high-
sensitivity C-reactive protein (hs-CRP) status (elevated versus normal), prior disease-modifying 
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antirheumatic drugs (DMARDs) use (yes versus no), TJC78, SJC76, enthesitis count (0-29), 
dactylitis count (0-20), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 
Ankylosing Spondylitis Disease Activity Score (ASDAS), PtGA (0-100mm VAS), PhGA (0-
100mm VAS), and treatment groups (adalimumab versus placebo). 




Patients enrolled in ABILITY-2 had generally comparable demographic and baseline disease 
characteristics, except for mean age which was higher in the adalimumab group and the 
percentage of patients with a dactylitis count >1 which was lower in the adalimumab group 
versus placebo.(4) Patients with pSpA receiving adalimumab achieved significantly greater 
clinical responses compared with placebo at week 12 and the efficacy was maintained over 3 
years.(4, 14)  
Correlation between mMDA and other pSpA outcome measures 
To explore the relationship between mMDA and pSpA outcome measures used in prior 
clinical trials, response rates were compared at week 12, and years 1-3. All 4 versions of mMDA 
response showed a stronger positive correlation with PSpARC remission (rtet >0.95) compared 
with ASDAS ID (rtet >0.75) at week 12 and years 1-3 (Table 1). There was a moderate negative 
correlation between the 4 versions of mMDA response and PhGA (rpb=0.43–0.61) at week 12 
and years 1-3. However, the 4 versions of mMDA did not correlate with CRP levels (data not 
shown). Correlation with patient global was not performed as patient global is part of the MDA.  
Achievement of mMDA over 3 years 
Among 163 patients (82 adalimumab, 81 placebo) who completed week 12 of the double-
blind period of ABILITY-2, a significantly greater proportion of patients receiving adalimumab 
achieved mMDA (regardless of the definition) compared with placebo (p<0.001 for all 
comparisons, Figure 1). At week 12, 40.2%, 28.0%, 35.4%, and 26.8% of patients treated with 
adalimumab achieved mMDA based on LEI 4/6, LEI 5/6, SPARCC 4/6, and SPARCC 5/6, 
respectively, compared with 13.6%, 4.9%, 12.3%, and 4.9% of patients treated with placebo. 
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Among patients who achieved mMDA at week 12, 48.5% (LEI 4/6; N=16), 69.6% ( LEI 
5/6; N=16), 48.3% (SPARCC 4/6; N=14), and 63.6% (SPARCC 5/6; N=14) of adalimumab-
treated patients attained all 6 components of mMDA compared with only 18.2% (N=2), 50.0% 
(N=2), 20% (N=2), and 50.0% (N=2) of placebo-treated patients.  
During the open-label extension, the proportion of patients who achieved mMDA (as 
observed) were maintained over 3 years across all 4 versions (online supplementary Figure S1). 
However, the rate of mMDA achievement including sustained mMDA achievement was 
numerically higher at every time point among patients initially randomized to receive 
adalimumab compared with patients switching from placebo to adalimumab. 
Ability of mMDA for detection of treatment effect  
All 4 versions of mMDA had numerically higher Pearson’s χ2 values compared to 
PSpARC remission and ASDAS ID and showed the ability to detect significant efficacy 
difference between adalimumab and placebo treatment groups (Table 2). 
Individual mMDA components and criteria not met 
To establish the “threshold of meaning” of the measure, the individual mMDA 
components that were not achieved in adalimumab-treated patients achieving each version of 
mMDA were assessed to better understand their contribution to the overall response. Among 
patients receiving adalimumab who fulfilled 4/6 mMDA criteria (LEI or SPARCC) at week 12, 
the joint count criteria were most frequently not met (TJC: LEI 4/6, 27.3%; SPARCC 4/6, 
20.7%; SJC: LEI 4/6, 30.3%; SPARCC 4/6: 24.1%) (Table 3). However, the 5/6 criteria (LEI or 
SPARCC) were more stringent with approximately only 4% and 13% not meeting the TJC or 
SJC criterion, respectively. Approximately 5-10% of adalimumab-treated patients achieving 
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mMDA did not attain the HAQ-DI criterion. For enthesitis there was no big difference between 
the 4/6 or 5/6 mMDA versions but using LEI versions of mMDA adalimumab patients all 
attained the enthesitis criterion compared with 9% and 10% of patients not meeting this using 
mMDA versions with SPARCC, respectively.  
In adalimumab-treated patients achieving 4/6 mMDA criteria (LEI or SPARCC), the mean TJC 
and SJC were at or above the mMDA cut-off (online supplementary Table S2), while all other 
components were lower than the mMDA cut-off. The 5/6 mMDA criteria were more stringent 
with the mean of each MDA component lower than the mMDA cut-off. Among pSpA patients 
who did not achieve mMDA at week 12, 83-88% of adalimumab-treated patients achieved 1/6 
mMDA criteria (LEI or SPARCC), while the rate was 66-79% in placebo-treated patients (online 
supplementary Table S3). 
Predictors of long-term mMDA response 
Multiple logistic regression analyses were performed for the more stringent 5/6 mMDA 
definitions based on better face validity and identified mMDA response after 12 weeks of 
adalimumab exposure (mMDA12) as a strong and robust positive predictor of attaining both 
long-term mMDA at years 1–3 and sustained mMDA (p<0.001 for the 5/6 mMDA definitions, 
using either LEI [OR range: 11.38 – 27.13] or SPARCC [OR range: 17.98 – 37.85], at years 1–3 
and sustained over time, Figure 2). In contrast, baseline BASDAI was a consistent negative 
predictor of mMDA achievement at years 1–3 and sustained over time, irrespective of the 
inclusion of LEI (OR range: 0.36 – 0.66) or SPARCC (OR range: 0.51 – 0.68) in the mMDA 
definition (Figure 2). Although prior DMARD use and baseline PhGA were selected as positive 
predictors and baseline enthesitis was selected as a negative predictor, these variables did not 
consistently predict mMDA achievement at every time point or sustained over time and were 
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only weakly associated. ASDAS showed positive association with mMDA achievement at year 
3.  
An analysis excluding ASDAS was performed as ASDAS and BASDAI are highly 
correlated outcomes. The analysis showed that both mMDA12 and BASDAI were still 
significantly associated with mMDA achievement at year 3 (online supplementary Figure S2). 
In addition, hs-CRP showed a positive association with mMDA achievement at year 3; elevated 
baseline hs-CRP was associated with increased likelihood of achieving mMDA.  
In the model examining the baseline variables alone (model without mMDA12), age, 
enthesitis, and BASDAI scores were most commonly selected as negative predictors for 
achieving long-term response over 3 years and sustained mMDA (Figure 3). Baseline PhGA, hs-
CRP, and male sex were selected as positive predictors and dactylitis was selected as negative 
predictor; however, these predictors were not consistently selected for all time points or 
sustained mMDA. 
The mMDA response rates (probability of achieving mMDA response) at years 1–3 and 
sustained over time in patients who achieved mMDA after 12 weeks of adalimumab exposure 
(mMDA12) compared with patients who did not achieve mMDA12 are shown in online 
supplementary Table S4. The response rate was consistent with the model selection results, 
indicating that patients who achieved mMDA after 12 weeks of ADA exposure were 80–90% 
more likely to achieve mMDA response at years 1–3 and sustained over time. 




The MDA has been established as a valid composite outcome measure and appropriate 
treatment target in patients with PsA.(19, 20) The present analyses evaluated the potential 
applicability and performance of a modification of the MDA following principles of the 
OMERACT filter in patients with non-psoriatic pSpA from the ABILITY-2 study and identified 
predictors of long-term mMDA responses following adalimumab treatment.  
Given that there is no established gold standard in pSpA, criterion validity could not be 
assessed. Therefore, we evaluated concurrent validity which assesses how the mMDA compares 
with other measures to measure similar constructs (pSpARC and ASDAS). All 4 versions of 
mMDA criteria showed strong positive correlations with PSpARC remission and ASDAS ID, 
disease-specific outcome measures in pSpA underlining the validity of applying mMDA criteria 
to pSpA. Among the response criteria evaluated, all 4 mMDA versions, the PSpARC remission, 
and ASDAS ID overall discriminated well between adalimumab and placebo treatment groups 
and the mMDA version that used either of the PsA validated entheseal indices (LEI and 
SPARCC) performed comparably.  
Similar to MDA definitions used in PsA, the data presented here support the concurrent 
validity and discrimination of mMDA using either entheseal index depending on physician’s 
preference.  
At week 12, nearly 35-40% of patients treated with adalimumab achieved 4/6 versions of 
mMDA, while 27-28% achieved the more stringent 5/6 versions of mMDA. The proportions of 
patients achieving mMDA was maintained over 3 years across the different mMDA definitions, 
reaching up to 58-60% in patients initially randomized to adalimumab and continued therapy. 
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Throughout the duration of the study (3 years), sustained mMDA was achieved by 55% (4/6 
versions) and 44% (5/6 versions) of patients initially treated with adalimumab. The sustained 
mMDA rates using the more stringent 5/6 versions of LEI or SPARCC are similar to rates 
observed in previous studies.(21, 22) Also, at week 12, 17-20% of patients receiving 
adalimumab achieved 6/6 versions of mMDA, which is in accordance to MDA 7/7 rates reported 
in patients with PsA.(23, 24) 
In PsA, MDA requires achievement of 5/7 criteria. However, the MDA criteria were 
modified for the non-psoriatic pSpA population by removing the psoriasis skin component 
(PASI); with this modification it was unclear if 4/6 or 5/6 would perform best in pSpA. 
Concurrent validity and treatment discrimination were similar for both the 4/6 and 5/6 versions, 
so residual disease was examined to compare these further. Among adalimumab-treated patients 
who achieved 4/6 versions of mMDA at week 12, joint responses (TJC and SJC) were most often 
the limiting factors in mMDA attainment. In patients achieving 5/6 versions of mMDA, SJC 
followed by HAQ-DI (LEI) or enthesitis (SPARCC) appeared to limit mMDA achievement but 
residual levels of disease were much lower. Interestingly, all adalimumab-treated patients 
achieving mMDA based on LEI met the enthesitis criterion, whereas 9-10% failed to meet 
enthesitis criterion based on SPARCC. This difference is likely attributed to more sites being 
assessed in SPARCC compared with LEI. More studies are needed to assess whether LEI or 
SPARCC might be more appropriate to use in pSpA.  
Although most mMDA components were below the mMDA cut-off in adalimumab-
treated patients achieving 4/6 mMDA criteria, the mean TJC and SJC were at or above the 
mMDA cut-off. In contrast, the mean for all mMDA components was below the mMDA cut-off 
in adalimumab-treated patients achieving 5/6 versions. A measure of minimal disease activity or 
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a treatment target should be associated with low levels of residual disease for face validity.  The 
5/6 mMDA versions were more stringent than 4/6 versions and more closely represent the 
concept of MDA with low values for most of the mMDA components. Thus, to summarize, the 
5/6 mMDA with either entheseal measures, rather than the 4/6 mMDA, could be an appropriate 
response measure in pSpA patients. 
Multiple logistic regression analysis identified achievement of either 5/6 versions of 
mMDA (mMDA 5/6 (LEI) or mMDA 5/6 (SPARCC) after 12 weeks of adalimumab exposure as 
the strongest and most consistent predictors of long-term mMDA, whether at 1, 2, or 3 years or 
sustained over time. That early clinical response is predictive of long-term response is in line 
with other studies in PsA, AS, or pSpA.(22, 25, 26) In PsA patients treated with certolizumab 
pegol, early clinical response at week 12 was identified as a positive predictor of MDA response 
at week 48.(27) Previously, achievement of early response at week 12 in AS patients receiving 
adalimumab was found to be most predictive of long-term treatment response.(28) Recently, in 
patients with pSpA from ABILITY-2, ASDAS ID or PSpARC remission at week 12 were shown 
to predict subsequent long-term and sustained treatment response.(14) All other variables 
including baseline BASDAI were either only marginal predictors and/or did not reliably or 
consistently predict mMDA response at every time point or sustained over time. In several 
studies evaluating predictors of MDA response in patients with PsA, baseline HAQ-DI was most 
often reported as a negative predictor of long-term MDA.(22, 25, 26)  
Limitations of the current analysis include the limited sample size in each treatment arm, 
and the lack of PASI in the MDA definition. However, ABILITY-2 had both a placebo-
controlled period and long-term open-label extension, allowing the validation of mMDA in a 
pSpA patient population and identification of predictors of long-term treatment response. As 
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there is no gold standard in pSpA we used concurrent validity to assess the performance of 
mMDA versions compared to other available outcome measures that have been used in the past 
in pSpA. Correlation analyses were only performed with a limited number of other endpoints 
such as PSpARC or ASDAS ID as few outcome measures are established in this disease. This 
analysis did not aim to address all aspects of the OMERACT filter systematically so further work 
is required, using different methodology to address truth (content and face validity), feasibility 
and reliability. However, it should be noted that the original MDA has been proven to be 
feasible, so the modifications by definition should also be feasible given that one domain was 
removed. The performance of the mMDA could not be analyzed in subgroups of pSpA patients 
with dactylitis, inflammatory bowel disease (IBD), or uveitis due to the limited sample size of 
these subgroups. While the mMDA criteria could reasonably be applied to pSpA patients with 
dactylitis as it evaluates the tender and swollen joints, further studies are needed for patients with 
IBD or uveitis. 
In summary, mMDA using 5/6 criteria in pSpA appears to be a valid, discriminative 
measure to assess treatment differences in patients with pSpA, and achievement of early mMDA 
response following adalimumab treatment was the most robust and consistent predictor of long-
term mMDA response. 
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independent scientific research, and will be provided following review and approval of a 
research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing 
Agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 
12 months, with possible extensions considered. For more information on the process, or to 
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submit a request, visit the following link: https://www.abbvie.com/our-science/clinical-
trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-
researchers.html 
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4/6 LEI     
PSpARC Remissiona 0.99* 0.99 0.96 0.99 
ASDAS IDa 0.82 0.79 0.89 0.86 
PhGAb -0.50 -0.51 -0.51 -0.61 
5/6 LEI     
PSpARC Remissiona 0.98 0.98 0.97 0.99* 
ASDAS IDa 0.82 0.80 0.88 0.84 
PhGAb -0.44 -0.47 -0.54 -0.55 
4/6 SPARCC     
PSpARC Remissiona 0.99 0.99 0.96 0.99 
ASDAS IDa 0.76 0.76 0.89 0.85 
PhGAb -0.49 -0.55 -0.54 -0.58 
5/6 SPARCC     
PSpARC Remissiona 0.97 0.98 0.97 0.99 
ASDAS IDa 0.80 0.79 0.86 0.83 
PhGAb -0.43 -0.46 -0.50 -0.54 
aTetrachoric correlation. 
bPoint biserial correlation. 
*Value >0.99  
ASDAS ID=Ankylosing Spondylitis Disease Activity Score for Inactive Disease; DB=double-
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blind period; LEI=Leeds Enthesitis Index; MDA=Minimal Disease Activity; OLE=Open-Label 
Extension; PhGA=Physician’s Global Assessment of disease activity; pSpA=Peripheral 
SpondyloArthritis; PSpARC=Peripheral SpondyloArthritis Response Criteria; 
SPARCC=Spondyloarthritis Research Consortium of Canada. 
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mMDA 4/6 (LEI) 33/82 (40.2) 11/81 (13.6) 14.70 <0.001 
mMDA 5/6 (LEI) 23/82 (28.0) 4/81 (4.9) 15.75 <0.001 
mMDA 4/6 (SPARCC) 29/82 (35.4) 10/81 (12.3) 11.86 <0.001 
mMDA 5/6 (SPARCC) 22/82 (26.8) 4/81 (4.9) 14.57 <0.001 
PSpARC remission 33/81 (40.7) 16/80 (20.0) 8.18 0.004 
ASDAS ID 27/80 (33.8) 12/78 (15.4) 7.17 0.007 
an (%) 
LEI=Leeds Enthesitis Index; MDA=Minimal Disease Activity; OLE=Open-Label Extension; 
pSpA=Peripheral SpondyloArthritis; PSpARC=Peripheral SpondyloArthritis Response Criteria; 
SPARCC=Spondyloarthritis Research Consortium of Canada. 
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Table 3. Criteria not met in modified MDA achievers receiving adalimumab at week 12 
Modified MDA, n 
(%) 
Modified MDA criterion, n (%) 









4/6 LEI (n=33) 9 (27.3) 10 (30.3) 2 (6.1) 3 (9.1) 3 (9.1) 0 (0.0) 
5/6 LEI (n=23) 1 (4.3) 3 (13.0) 0 (0.0) 1 (4.3) 2 (8.7) 0 (0.0) 
4/6 SPARCC (n=29) 6 (20.7) 7 (24.1) 1 (3.4) 2 (6.9) 3 (10.3) 3 (10.3) 
5/6 SPARCC (n=22) 1 (4.5) 3 (13.6) 0 (0.0) 1 (4.5) 1 (4.5) 2 (9.1) 
DB=double-blind period; HAQ-DI=Health Assessment Questionnaire-Disability Index based on 20 questions; 
LEI=Leeds Enthesitis Index; MDA=Minimal Disease Activity; OLE=Open-Label Extension; PtGA=Patient Global 
assessment of disease Activity; Patient Pain=Patient global assessment of Pain; SJC76=Swollen Joint Count (76 
joints); SPARCC=Spondyloarthritis Research Consortium of Canada; TJC78=Tender Joint Count (78 joints); 
VAS=Visual Analog Scale. 




Figure 1. Achievement of modified MDA (as observed) at week 12, and years 1 through 3 in 
patients receiving adalimumab (black bars), placebo (white bars), or switching from placebo to 
adalimumab at week 12 (grey-shaded bars) using four definitions of mMDA.  
P-values for difference between adalimumab and placebo or placebo/adalimumab treatment 
groups: ***, P<0.001; **, P<0.01; *, P<0.05. 
LEI=Leeds Enthesitis Index; MDA=Minimal Disease Activity; SPARCC=Spondyloarthritis 
Research Consortium of Canada. 
Figure 2. Baseline and Week 12 Factors Associated with Long-term and sustained mMDA 
Responses Predictors of Long-term (Years 1–3) and Sustained mMDA Responses from Multiple 
Logistic Regression Model Including mMDA12. 
*Only variables selected by stepwise selection model are shown (model selected variables are 
significant at P<.05). 
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing 
Spondylitis Disease Activity Index; CI, confidence interval; DMARDs, disease modifying 
antirheumatic drugs; hs-CRP, high sensitivity C-reactive protein; mMDA12, modified Minimal 
Disease Activity response following 12 weeks of adalimumab treatment; LEI, Leeds enthesitis 
index; PhGA, physician’s global assessment of disease activity; SJC76, swollen joint count (76 
joints); SpA, spondyloarthritis; SPARCC = Spondyloarthritis Research Consortium of Canada 
enthesitis index. 
 
mMDA in pSpA 
29 
 
Figure 3. Baseline Factors Associated With mMDA Long-term and Sustained Responses 
Predictors of Long-term (Years 1–3) and Sustained mMDA Responses from Multiple Logistic 
Regression Model Without mMDA12* 
*Only variables selected by stepwise selection model are shown (model selected variables are 
significant at P<.05) 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CI, confidence interval; hs-CRP, 
high sensitivity C-reactive protein; LEI, Leeds enthesitis index; mMDA12, modified minimal 
disease activity response following 12 weeks of adalimumab treatment; PhGA, physician’s 
global assessment of disease activity; SJC76, swollen joint count (76 joints); SPARCC, 
Spondyloarthritis Research Consortium of Canada enthesitis index 
